Clinical trial
Karenitecin in Treating Patients With Persistent or Recurrent Ovarian Epithelial…
NCT00054119 · Gynecologic Oncology Group, Other · Completed
Key facts
| NCT number | NCT00054119 |
|---|---|
| Title | Karenitecin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer |
| Official title | A Phase II Evaluation of Karenitecin in the Third-Line Treatment of Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma |
| Lead sponsor | Gynecologic Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Primary Peritoneal Carcinoma, Recurrent Ovarian Carcinoma |
| Intervention type | Drug, Other |
| Interventions | Cositecan, Pharmacological Study |
| Enrollment | 27 |
| Start date | Jan 1, 2003 |
| Primary completion | Sep 30, 2005 |
| First posted | Feb 6, 2003 |
| Last update posted | Jul 13, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: